Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
Status:
Unknown status
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
Chronic GVHD is the most common late complication following allogeneic stem cell
transplantation. It has features resembling autoimmune disorders such as scleroderma, primary
biliary cirrhosis, bronchiolitis obliterans, chronic immunodeficiency etc. Thus, chronic GVHD
can lead to debilitating complications such as joint contractures, blindness, end-stage lung
disease, etc so that chronic GVHD has a major impact both on survival as well as quality of
life. Although its pathogenesis is still poorly unclear, it has been reported since 2000 that
B cell-mediated immunity may also contribute to development of chronic GVHD other than T
cells. Thus, targeting against B cell may be a useful treatment strategy in the treatment of
chronic GVHD.
The purpose of this study is to determine whether rituximab, an anti-CD20 monoclonal kimeric
antibody is effective in the treatment of chronic graft-versus-host disease (chronic GVHD)
refractory to steroid.
Phase:
Phase 2
Details
Lead Sponsor:
The Korean Society of Hematopoietic Stem Cell Transplantation